SCHEMBL7676746

SCHEMBL7676746

O=C1C(=Cc2ccccc2)c2ccccc2N1c1ncccn1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APP P05067 9/20 0.53
MAPT P10636 8/20 0.53
SNCA P37840 8/20 0.53
HCRTR1 O43613 1/20 0.50
ERBB2 P04626 1/20 0.46
ALDH1A1 P00352 2/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ITGA4 P13612 2/20 0.42
ITGB7 P26010 2/20 0.42
TRPA1 O75762 1/20 0.41
MDM4 O15151 1/20 0.39
TP53 P04637 1/20 0.39
MDM2 Q00987 1/20 0.39
CES2 O00748 1/20 0.38
BCHE P06276 1/20 0.38
GAA P10253 1/20 0.38
CES1 P23141 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7672585 0.87 APP (0.52) APPMAPTSNCAHCRTR1ERBB2
SCHEMBL7672581 0.87 APP (0.52) APPMAPTSNCAHCRTR1ERBB2
SCHEMBL7678889 0.81 APP (0.75) APPMAPTSNCAHCRTR1ERBB2
SCHEMBL7678890 0.81 APP (0.75) APPMAPTSNCAHCRTR1ERBB2
SCHEMBL7678131 0.80 MAPT (0.50) APPMAPTSNCAHCRTR1ERBB2
SCHEMBL7679531 0.80 TRPA1 (0.50) APPMAPTSNCAHCRTR1ERBB2
SCHEMBL7679532 0.80 TRPA1 (0.50) APPMAPTSNCAHCRTR1ERBB2
SCHEMBL7678126 0.80 MAPT (0.50) APPMAPTSNCAHCRTR1ERBB2
SCHEMBL8296193 0.78 MAPT (0.71) APPMAPTSNCAHCRTR1ERBB2
SCHEMBL8296195 0.78 MAPT (0.71) APPMAPTSNCAHCRTR1ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020028936-A1 1,3-disubstituted indolin-2-ones for neoplasia OSI PHARMACEUTICALS, INC. 2002-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028936-A1 1,3-disubstituted indolin-2-ones for neoplasia TP53, MYC, VHL APP 4305/4885MAPT 2381/4885SNCA 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.